Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, Noel W, Schett G, Mcinnes IB (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

DOI: 10.1136/annrheumdis-2021-220991

Abstract

Objective To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFi).

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

University of Oxford GB United Kingdom (GB) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne FR France (FR) Janssen Global Services, LLC US United States (USA) (US) Janssen-Cilag GmbH DE Germany (DE) Janssen Pharmaceutica NV BE Belgium (BE) Janssen Biologics BV NL Netherlands (NL) University of Glasgow GB United Kingdom (GB)

How to cite

APA:

Coates, L.C., Gossec, L., Theander, E., Bergmans, P., Neuhold, M., Karyekar, C.S.,... Mcinnes, I.B. (2021). Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Annals of the Rheumatic Diseases. https://dx.doi.org/10.1136/annrheumdis-2021-220991

MLA:

Coates, Laura C., et al. "Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)." Annals of the Rheumatic Diseases (2021).

BibTeX: Download